ASHOKLEY.NSE

Ashok Leyland Ltd.

Union Minister for Road Transport and Highways Nitin Gadkari on Tuesday said vehicles running on petrol and diesel have no long-term future, urging the automobile industry to shift towards cleaner fuel alternatives. Speaking at the Busworld India Conclave 2025, Gadkari backed the transition to green mobility, stressing that fossil fuels pose serious challenges due to rising imports and environmental concerns. His remarks come amid India’s push to reduce carbon emissions and promote sustainable transport systems. Shift Towards shift towards cleaner fuels Gadkari emphasised that manufacturers must accelerate the move towards biofuels, CNG, LNG, and electric vehicles. He also highlighted ongoing efforts in hydrogen mobility, calling it the “fuel of the future.” “We are running hydrogen trucks and buses on multiple routes,” he said, adding that leading automakers are already participating in pilot projects. Companies such as Tata Motors, Volvo, Ashok Leyland, and Mahindra & Mahindra are involved in hydrogen fuel trials.

Nitin Gadkari also said major Indian companies, including Tata Motors, Volvo, Ashok Leyland, and Mahindra & Mahindra, are already involved in hydrogen fuel trials as the government has already begun hydrogen mobility projects.

Nitin Gadkari also said major Indian companies, including Tata Motors, Volvo, Ashok Leyland, and Mahindra & Mahindra, are already involved in hydrogen fuel trials as the government has already begun hydrogen mobility projects.

India’s CV segment posts strong double-digit growth in March 2026 with Tata Motors in the with 35.48% market share The post CV Retail Sales March and FY 2026 – Tata, Mahindra, Ashok Leyland, VECV, Maruti, Force, Daimler appeared first on RushLane .

India’s CV segment posts strong double-digit growth in March 2026 with Tata Motors in the with 35.48% market share The post CV Retail Sales March and FY 2026 – Tata, Mahindra, Ashok Leyland, VECV, Maruti, Force, Daimler appeared first on RushLane .

In this briefing: APAC Healthcare Weekly (April 12) – Wuxi XDC, Xuanzhu Biopharma, Shionogi, ABL Bio, PharmaEssentia Will Hybrid-Attendance and Virtual-Only Shareholder Meetings Become More Common? Weekly Deals Digest (12 Apr) - Victory Giant, Huaqin, Manycore, Sigenergy, Global, Olympic, Sankei Delhi's EV Draft Policy: Who Wins the Policy Windfall of 2026–2030? Indian Geospatial: Why MapmyIndia’s Platform Beats Genesys’s Project-Led Growth 1. APAC Healthcare Weekly (April 12) – Wuxi XDC, Xuanzhu Biopharma, Shionogi, ABL Bio, PharmaEssentia Wuxi XDC partnered with Akari Therapeutics to accelerate IND filing for Akari’s ADC program. Xuanzhu Biopharmaceutical entered licensing agreement with Boston Oncology for upfront and milestone payments of $100M+. Shionogi secured $119M BARDA contract for manufacturing, procurement, and expanded development of Fetroja for biothreat-related infections. ABL Bio’s partner has received Orphan Drug Designation from the FDA for tovecimig. PharmaEssentia signed an investment agreement for a new manufacturing facility in Puerto Rico.

In this briefing: APAC Healthcare Weekly (April 12) – Wuxi XDC, Xuanzhu Biopharma, Shionogi, ABL Bio, PharmaEssentia Will Hybrid-Attendance and Virtual-Only Shareholder Meetings Become More Common? Weekly Deals Digest (12 Apr) - Victory Giant, Huaqin, Manycore, Sigenergy, Global, Olympic, Sankei Delhi's EV Draft Policy: Who Wins the Policy Windfall of 2026–2030? Indian Geospatial: Why MapmyIndia’s Platform Beats Genesys’s Project-Led Growth 1. APAC Healthcare Weekly (April 12) – Wuxi XDC, Xuanzhu Biopharma, Shionogi, ABL Bio, PharmaEssentia Wuxi XDC partnered with Akari Therapeutics to accelerate IND filing for Akari’s ADC program. Xuanzhu Biopharmaceutical entered licensing agreement with Boston Oncology for upfront and milestone payments of $100M+. Shionogi secured $119M BARDA contract for manufacturing, procurement, and expanded development of Fetroja for biothreat-related infections. ABL Bio’s partner has received Orphan Drug Designation from the FDA for tovecimig. PharmaEssentia signed an investment agreement for a new manufacturing facility in Puerto Rico.

In this briefing: APAC Healthcare Weekly (April 12) – Wuxi XDC, Xuanzhu Biopharma, Shionogi, ABL Bio, PharmaEssentia Gas Insecurity: India Imports 36 BCM of LNG Annually, Stores Almost None of It! Primer: Shaily Engineering Plastics (SHEP IN) - Apr 2026 True Cost of Running an AI Data Centre: A Unit Economics Breakdown Delhi's EV Draft Policy: Who Wins the Policy Windfall of 2026–2030? 1. APAC Healthcare Weekly (April 12) – Wuxi XDC, Xuanzhu Biopharma, Shionogi, ABL Bio, PharmaEssentia Wuxi XDC partnered with Akari Therapeutics to accelerate IND filing for Akari’s ADC program. Xuanzhu Biopharmaceutical entered licensing agreement with Boston Oncology for upfront and milestone payments of $100M+. Shionogi secured $119M BARDA contract for manufacturing, procurement, and expanded development of Fetroja for biothreat-related infections. ABL Bio’s partner has received Orphan Drug Designation from the FDA for tovecimig. PharmaEssentia signed an investment agreement for a new manufacturing facility in Puerto Rico.

In this briefing: APAC Healthcare Weekly (April 12) – Wuxi XDC, Xuanzhu Biopharma, Shionogi, ABL Bio, PharmaEssentia Gas Insecurity: India Imports 36 BCM of LNG Annually, Stores Almost None of It! Primer: Shaily Engineering Plastics (SHEP IN) - Apr 2026 True Cost of Running an AI Data Centre: A Unit Economics Breakdown Delhi's EV Draft Policy: Who Wins the Policy Windfall of 2026–2030? 1. APAC Healthcare Weekly (April 12) – Wuxi XDC, Xuanzhu Biopharma, Shionogi, ABL Bio, PharmaEssentia Wuxi XDC partnered with Akari Therapeutics to accelerate IND filing for Akari’s ADC program. Xuanzhu Biopharmaceutical entered licensing agreement with Boston Oncology for upfront and milestone payments of $100M+. Shionogi secured $119M BARDA contract for manufacturing, procurement, and expanded development of Fetroja for biothreat-related infections. ABL Bio’s partner has received Orphan Drug Designation from the FDA for tovecimig. PharmaEssentia signed an investment agreement for a new manufacturing facility in Puerto Rico.